文献速递神经MR

基于MRI的影像组学与空间分布联合模型鉴别多发性硬化、视神经脊髓炎谱系疾病和髓鞘少突胶质细胞糖蛋白抗体相关疾病

Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
PubMed 文献 · Eur Radiol · 2023-12-21

本研究在212例脑MRI扫描中勾画T2高信号病灶,提取351个影像组学特征和27个空间分布特征,构建多病灶影像组学、空间分布及联合模型,并联合年龄和性别建立鉴别MS与MOGAD-NMOSD的判别器,最终形成三疾病鉴别流程,其准确率75.0%,优于三名放射科医师的47.6%、56.6%和66.0%。

要点

  • 联合模型在区分MS与其他疾病以及MOGAD与NMOSD时均优于单独影像组学或空间分布模型。
  • 三疾病鉴别流程准确率75.0%,高于三名放射科医师的47.6%、56.6%和66.0%。
  • MS判别器AUC为0.909±0.027,MOG-NMO判别器AUC为0.880±0.064。

核心结论

  • 整合多病灶影像组学和空间分布特征的流程能有效鉴别MS、NMOSD和MOGAD,可能有助于这三种疾病的鉴别诊断。

研究设计与样本

  • 研究纳入212例脑MRI扫描,其中MS 63例、NMOSD 87例、MOGAD 45例,勾画T2高信号病灶后提取351个影像组学特征和27个空间分布特征,采用随机森林和逻辑回归算法构建模型,并通过交叉验证评估。

诊断标准与关键数值

  • MS判别器AUC=0.909±0.027,偏倚校正C-index=0.909±0.027;MOG-NMO判别器AUC=0.880±0.064,偏倚校正C-index=0.883±0.068;三疾病鉴别流程准确率75.0%,三名放射科医师准确率分别为47.6%、56.6%和66.0%。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To develop a discrimination pipeline concerning both radiomics and spatial distribution features of brain lesions for discrimination of multiple sclerosis (MS), aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD), and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder (MOGAD).

METHODS: Hyperintensity T2 lesions were delineated in 212 brain MRI scans of MS (n = 63), NMOSD (n = 87), and MOGAD (n = 45) patients. To avoid the effect of fixed training/test dataset sampling when developing machine learning models, patients were allocated into 4 sub-groups for cross-validation. For each scan, 351 radiomics and 27 spatial distribution features were extracted. Three models, i.e., multi-lesion radiomics, spatial distribution, and joint models, were constructed using random forest and logistic regression algorithms for differentiating: MS from the others (MS models) and MOGAD from NMOSD (MOG-NMO models), respectively. Then, the joint models were combined with demographic characteristics (i.e., age and sex) to create MS and MOG-NMO discriminators, respectively, based on which a three-disease discrimination pipeline was generated and compared with radiologists.

RESULTS: For classification of both MS-others and MOG-NMO, the joint models performed better than radiomics or spatial distribution model solely. The MS discriminator achieved AUC = 0.909 ± 0.027 and bias-corrected C-index = 0.909 ± 0.027, and the MOG-NMO discriminator achieved AUC = 0.880 ± 0.064 and bias-corrected C-index = 0.883 ± 0.068. The three-disease discrimination pipeline differentiated MS, NMOSD, and MOGAD patients with 75.0% accuracy, prominently outperforming the three radiologists (47.6%, 56.6%, and 66.0%).

CONCLUSIONS: The proposed pipeline integrating multi-lesion radiomics and spatial distribution features could effectively differentiate MS, NMOSD, and MOGAD.

CLINICAL RELEVANCE STATEMENT: The discrimination pipeline merging both radiomics and spatial distribution features of brain lesions may facilitate the differential diagnoses of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.

KEY POINTS: • Our study introduces an approach by combining radiomics and spatial distribution models. • The joint model exhibited superior performance in distinguishing multiple sclerosis from aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder as well as discriminating the latter two diseases. • The three-disease discrimination pipeline showcased remarkable accuracy, surpassing the performance of experienced radiologists, highlighting its potential as a valuable diagnostic tool.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Luo X, Li H, Xia W, et al. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder. Eur Radiol. 2023. PMID: 38127076. doi:10.1007/s00330-023-10529-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。